20th October is “World Osteoporosis Day,” which is organised by The International Osteoporosis Foundation (IOF). The aim: to raise awareness of bone disease, which is one of the 10 most common chronic diseases worldwide.[1] And this is essential, because knowledge about osteoporosis is sorely lacking.
Clonmel Healthcare’s parent company STADA conducted a Health Report in 2020 which shows that only 22 percent of Europeans know that osteoporosis can be caused by genetic predisposition. An early diagnosis can help to prevent damage to bones. It is interesting to note from the report that women (26 percent) are better informed about their genetic disposition than men (19 percent): because 80 percent of all those affected are women.[2]
201012_Osteoporosis_Infographic_v4Worldwide, every third woman and every fifth man over the age of fifty suffers a bone fracture due to osteoporosis.[3] Various treatment options are available, including biological drugs, for which cost-effective biosimilar alternatives are available. Those who know about the disease and possible predispositions can start preventive measures early. These include supplying the body with sufficient calcium and vitamin D and taking regular exercise to strengthen bones. This is because osteoporosis causes a decrease in bone density.[4] Depending on the progression of the disease, bones become porous and unstable to varying degrees. Preventive actions help to avoid fractures in so far as possible.
These are the results of the second international STADA Health Report 2020, a representative study with more than 24,000 respondents from twelve countries. On behalf of STADA Arzneimittel AG, the Kantar market research institute interviewed around 2,000 people aged between 18 and 99 years from Austria, Belgium, Finland, France, Germany, Italy, Poland, Russia, Serbia, Spain, Switzerland and the United Kingdom on the topic of “The road to the future of health”. Further information on the STADA Health Report and much more can be found at: www.yourhealth.stada.
Clonmel Healthcare offers a treatment option in the form of the biosimilar Movymia®. The active ingredient teriparatide contained in the product is used in the therapy of osteoporosis patients. Movymia® is administered via a reusable, multi-dosage injection device; the “Movymia® Pen”. The pen is designed to be used for the entire duration of the treatment.
Other treatment options for Osteoporosis from Clonmel Healthcare include Binosto (Alendronic Acid) 70mg effervescent tablets, which is a buffered alendronate solution. A copy of the SmPC is available upon request or alternatively please go to www.clonmelhealthcare.ie
Medicinal products subject to medical prescription.
Binosto Once Weekly 70 mg effervescent tablets (PA 126/280/001)
Movymia 20 micrograms/80 microliters solution for injection (EU/1/16/1161/001 – 003)
PA Holder: Clonmel Healthcare Ltd., Clonmel, Co. Tipperary.
Date prepared: October 2020 2020/ADV/OST/089H
[1] https://www.osteoporose-deutschland.de/osteoporose/daten-und-fakten/ (consulted 18.09.2020)
2 https://www.osteoporose-deutschland.de/osteoporose/daten-und-fakten/ (consulted 18.09.2020)
3 https://www.osteoporosis.foundation/patients/about-osteoporosis
4 https://www.bzga.de/presse/pressearchiv/pressemitteilungen-2016/2016-10-19-echte-knochenarbeit-osteoporose-praevention/ consulted 18.09.2020)
